Subcutaneous Administration of Denosumab

Clinical Evidence

The American College of Physicians recommends subcutaneous administration of denosumab 60 mg every 6 months, as consistently used in multiple large-scale clinical trials, including the ABCSG-18 trial, D-CARE trial 1, 2, 3, 4
The ABCSG-18 trial used subcutaneous denosumab 60 mg every 6 months, with patients receiving the injection subcutaneously 2, 3, 4
The D-CARE trial administered denosumab 120 mg subcutaneously, highlighting the importance of subcutaneous administration 2, 3, 4

The American Academy of Family Physicians notes that calcitonin-salmon (Miacalcin) can be given subcutaneously or intramuscularly every other day, in contrast to denosumab's subcutaneous administration 1
Teriparatide (Forteo) is administered subcutaneously at a dose of 20 mcg per day, while zoledronic acid (Reclast) is administered intravenously, highlighting the unique administration route of denosumab 1